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 Background: Allergic rhinitis (AR) has high prevalence and substantial socio-economic burden.
 Material/Methods: The study included 35 Italian Centers recruiting an overall number of 3383 adult patients with rhinitis (48% 
males, 52% females, mean age 29.1, range 18–45 years). For each patient, the attending physician had to fill 
in a standardized questionnaire, covering, in particular, some issues such as the ARIA classification of allergic 
rhinitis (AR), the results of skin prick test (SPT), the kind of treatment, the response to treatment, and the sat-
isfaction with treatment.
 Results: Out of the 3383 patients with rhinitis, 2788 (82.4%) had AR: 311 (11.5%) had a mild intermittent, 229 (8.8%) a 
mild persistent, 636 (23.5%) a moderate-severe intermittent, and 1518 (56.1%) a moderate-severe persistent 
form. The most frequently used drugs were oral antihistamines (77.1%) and topical corticosteroids (60.8%). 
The response to treatment was judged as excellent in 12.2%, good in 41.3%, fair in 31.2%, poor in 14.5%, and 
very bad in 0.8% of subjects. The rate of treatment dissatisfaction was significantly higher in patients with 
moderate-to-severe AR than in patients with mild AR (p<0.0001). Indication to allergen immunotherapy (AIT) 
was significantly more frequent (p<0.01) in patients with severe AR than with mild AR.
 Conclusions: These findings confirm the appropriateness of ARIA guidelines in classifying the AR patients and the associ-
ation of severe symptoms with unsuccessful drug treatment. The optimal targeting of patients to be treated 
with AIT needs to be reassessed.
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Background
Allergic diseases show a continuous increase worldwide, with a 
major role for allergic rhinitis (AR), which currently has a prev-
alence up to 40%, but with significant differences in urban and 
rural environments (higher in rural areas) [1–3]. Among the 
possible explanations of such increase, childhood infections 
and exposure to certain microbial antigens seem to present a 
strong negative correlation with allergies, giving birth to the 
“Hygiene Hypothesis” as a possible cause of the rise of the al-
lergic burden in Western countries [4]. The importance of AR 
is further highlighted by its substantial social and economic 
costs [5,6], and to the impairment of patient’s daily activities 
and productivity [7–9]. AR was long classified as seasonal or 
perennial according to its duration, related for the former to 
sensitization to pollens or moulds and for the latter to house 
dust mites or animal epithelia, but the Allergic Rhinitis and its 
Impact on Asthma (ARIA) document, endorsed by the World 
Health Organization and published in 2001, introduced a new 
classification of AR based on duration and severity of symp-
toms [10]. ARIA distinguished intermittent AR (IAR), defined 
by symptoms occurring for <4 days/week for <4 consecutive 
weeks, from persistent AR (PER), defined by symptoms occur-
ring for >4 days/week for >4 consecutive weeks. Moreover, a 
severity scale of mild to moderate-severe symptoms (based on 
the AR impact on activities and quality of life) was proposed 
[10]. The ARIA classification was validated in 2003 [11] and is 
currently widely used worldwide. A multicenter study, named 
SURF (Survey of Rhinitis Features), was aimed at addressing 
the phenotypes of AR in a large population of children and 
adults. The results in children were already reported [12] and 
here we present the data concerning the adult population.
Material and Methods
The SURF study included 35 centers throughout Italy, recruit-
ing a total of 3383 adult patients presenting with rhinitis 
(48% males, 52% females, mean age 29.1 years, range 18–45 
years). For each patient, the attending physician had to fill in 
a standardized questionnaire, which was previously validat-
ed by the Federazione delle Società Italiane di Immunologia, 
Allergologia e Immunologia Clinica (IFIACI). The issues assessed 
by the questionnaire were: ARIA classification of rhinitis, kind 
and duration of symptoms, results of skin prick tests (SPT), 
allergen identified as clinically relevant, co-morbidities, treat-
ment plan, response to treatment, satisfaction with the treat-
ment, and feasibility of allergen immunotherapy (AIT). The con-
tinuous parameters (based on numeric values) were reported 
as mean, median, and standard deviation, while the categor-
ical parameters (based on values that function as categories) 
were reported as contingency tables. Data were statistical-
ly analyzed by the chi-squared test for 2 data tables and by 
log-linear models for more than 2 data tables. A p value low-
er than 0.05 was considered significant. Correlations were an-
alyzed by linear regression.
Results
Out of the 3383 patients with rhinitis, 2788 (82.4%) had AR: 
of these, 311 (11.5%) had a mild intermittent, 229 (8.8%) had 
mild persistent, 636 (23.5%) had moderate-severe intermittent, 
and 1518 (56.1%) had moderate-severe persistent form; in 130 
cases the data was missing. The rate of patients with persistent 
rhinitis was significantly higher than that of intermittent rhi-
nitis (p<0.01). There were 595 (17.6%) patients who had oth-
er kind of rhinitis, the most common being idiopathic rhinitis 
(251 cases), non-allergic rhinitis with eosinophilia (NARES, 123 
cases), occupational rhinitis (68 cases), and infective rhinitis 
(58 cases). The mean duration of rhinitis was 7.0±7.2 years.
Concerning the sensitization, Table 1 shows all the allergens 
eliciting positive SPT and their clinical relevance as assessed 
by patient history. Table 2 reports the identified co-morbidi-
ties. Patients with no co-morbidities had a higher frequency 
of mild AR, while patients with 2 or more co-morbidities had 
a higher frequency of moderate-to-severe AR. The most fre-
quently used drugs were oral antihistamines (2150 patients, 
77.1%) and topical corticosteroids (1695 patients, 60.8%), fol-
lowed by anti-leukotrienes (412, 14.8%), anti-asthmatic drugs 
(392 patients, 14.1%), topical antihistamines (354, 12.7%), oral 
Allergen
Number of 
positive SPT
% of total according 
to clinical relevance
Grass pollen 1470 42.6%
House dust mites 1266 32.2%
Parietaria pollen 845 23.9%
Olive pollen 706 10.4%
Cypress pollen 625 11.4%
Betulacee pollen 560 10.2%
Animal epithelia 432 4.7%
Compositae pollen 318 3.6%
Other pollens 191 1.6%
Alternaria spores 127 1.5%
Foods 23 0.5%
Other allergens 798 9.3%
Table 1.  Allergens eliciting a positive skin prick test (SPT) and 
their clinical relevance.
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corticosteroids (177, 6.3%), nasal decongestants (117, 4.2%), 
chromones (78, 2.8%), and others (587, 21.1%). Response to 
treatment was available in 2760 completed questionnaires,: 
it was judged as excellent in 304 cases (12.2%), good in 1027 
(41.3%), fair in 775 (31.2%), poor in 359 (14.5%), and very 
bad in 19 (0.8%). Satisfaction with treatment was judged as 
very satisfactory in 340 cases (13.7%), satisfactory in 1425 
(57.3%), unsatisfactory in 703 (28.3%), and very unsatisfac-
tory in 18 (0.7%). The rate of dissatisfaction was significant-
ly higher in patients with moderate-to-severe AR than in pa-
tients with mild AR (p<0.0001). Figure 1 shows the correlation 
between response to treatment and patient satisfaction; this 
correlation was significant (p<0.01). Data on the viability of AIT 
showed that in 2024 cases (73.8%) the treatment was consid-
ered indicated. This concerned 144 patients (46.5%) with mild 
intermittent, 412 patients (65.4%) with mild persistent, 201 
patients (85.2%) with moderate-to-severe intermittent, and 
1200 patients (80.8%) with moderate-to-severe persistent AR. 
Indication to AIT was significantly more frequent (p<0.01) in pa-
tients with severe than with mild AR. Considering the 2 major 
causes, AIT was viewed as feasible in 28.6% of patients allergic 
to grass pollen and in 22.7% of patients allergic to dust mites.
Discussion
The introduction of the concept of disease phenotyping was 
very important, because phenotypization may significantly 
influence the choice of diagnostic tests, predict the response 
to specific treatments, and suggest the long-term prognosis 
[13]. In the past, different clinical phenotypes were proposed, 
based on the period of occurrence of symptoms, defining the 
2 forms of seasonal (the old “hay fever”) or perennial rhinitis 
[14], and on the predominance of sneezing and nasal discharge 
(sneezer/runners) or nasal blockage (blockers) [15]. However, 
the ARIA classification redefined the criteria for identifying the 
phenotype of patients with AR, by the duration – intermittent 
or persistent – regardless of the season, and the severity of 
symptoms with their impact in daily life, classified as mild and 
moderate-to-severe [9]. Recent studies showed that the ARIA 
severity classification clearly discriminates the impact of AR in 
all domains of quality of life and categorized symptom score 
[16], and that the ARIA classification was correlated with the 
nasal cytology, which showed different cell types and counts 
according to different severity, with higher counts of mast cells 
and lymphocyte/plasma cells in moderate-to-severe AR [17]. 
The SURF study was aimed at investigating the features of 
AR in a large population of children and adults. Several issues 
were assessed for their possible association with AR feature, 
including the results of SPT, the allergen identified as clinical-
ly relevant, the co-morbidities, the kind of treatment, the re-
sponse to treatment, the satisfaction with the treatment, and 
the feasibility of immunotherapy. Immunotherapy is the only 
available treatment working on causes of allergy, being able 
to reduce the immunological and clinical reactivity to the re-
sponsible allergen [18]. The findings must be discussed with 
the data, when available, from the literature. Concerning the 
culprit allergens, grass pollen and house dust mites were con-
firmed to be the 2 major causes of AR [19,20], with prevalence 
of moderate-to-severe disease and of persistent forms. This 
confirms the suitability of the ARIA classification, because the 
previous classification in seasonal and perennial forms would 
Co-morbidity Number of cases (%)
Conjunctivitis  1496 (53.7%)
Asthma  1053 (37.8%)
Sinusitis  382 (13.7%)
Sleep disturbances  228 (8.2%)
Nasal polyps  129 (4.6%)
Oral allergy syndrome  52 (1.9%)
Adenoids/tonsils 
hypertrophy
 48 (1.7%)
Urticaria  43 (1.5%)
Dermatitis  36 (1.3%)
Cough  37 (1.3%)
Anosmia  7 (0.3%)
Recurrent respiratory 
infections
 13 (0.5%)
Other  318 (11.4%)
Table 2. Reported co-morbidities in patients with AR.
Figure 1.  Correlation between patient satisfaction and response 
to therapy.
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have missed the clinical importance according to the duration 
for grass-pollen. Co-morbidities were more common in patients 
with moderate/severe AR, with the highest rate for conjuncti-
vitis, which was present in 54% of subjects, defining the pic-
ture of rhinoconjunctivitis, which occurs very frequently in pa-
tients with AR [21]. According with the literature, the other 2 
most common co-morbidities were asthma (~38%) and sinus-
itis (~14%) [22–26]. In treatment of AR, the most frequently 
used drugs were oral antihistamines (77%) and topical cortico-
steroids (61%), in accordance with the ARIA guidelines, which 
state the adequacy of these treatments based on the evidence 
from controlled trials [10,22]. In contrast, patient satisfaction 
with prescribed treatments is scantily investigated, despite its 
importance in compliance to treatment [27]. A study on adult 
allergic patients assessed satisfaction with antihistamines, 
showing that the second-generation agents were considered 
by both the patients and the physicians to be effective and 
well-tolerated [28]. However, a recent survey on adult patients 
with AR, mostly treated with antihistamines and nasal corti-
costeroids, found that only 33.5% were satisfied with treat-
ments; female gender, presence of co-morbidities, and sever-
ity of AR were factors significantly associated with treatment 
dissatisfaction [29]. In the present study, the response to treat-
ment, as assessed by the physician, was judged as excellent 
in 12%, good in 41.3%, fair in 31.2%, poor in 14.5%, and very 
bad in 0.8% of cases. Satisfaction with treatment was judged 
as very satisfactory in 14%, satisfactory in 57%, unsatisfactory 
in 28.3%, and very unsatisfactory in 0.7% of cases. Response 
to treatment and satisfaction were significantly correlated. As 
expected, dissatisfaction was significantly higher in patients 
with moderate-to-severe AR than in patients with mild AR 
(p<0.0001). This raises the issue of severe AR uncontrolled by 
drug treatment, which includes the form currently defined as 
severe chronic upper airway disease (SCUAD) [30]. In this clin-
ical form, a multifactorial etiology may underlie the develop-
ment of sinus-nasal inflammation not responsive to drugs [31].
Concerning the feasibility of AIT, our data show that in 2024 
cases (74%), the treatment was considered increasingly indi-
cated according to severity, ranging from 46% in mild intermit-
tent to 81% in moderate-to-severe persistent AR. Focusing on 
the 2 major causes of AR, AIT was viewed as feasible in 28% 
of patients allergic to grass pollen and in 23% of patients al-
lergic to dust mites. Comparing the findings from the present 
study with those from the previous part of the SURF study on 
children [12] is of clear interest. Resulted of all the examined 
features were comparable, with the exception of the presence 
of adenoids/tonsils hypertrophy, which was significantly more 
frequent in children than in adults (6.6% vs. 1.7, p<0.0001). 
This is quite obvious, because this pathology is typically pediat-
ric, but recent immunological data suggest the need to recon-
sider the approach to hypertrophy of adenoids/tonsils (which 
are immunological organs belonging to the Waldeyer’s ring), 
which is mostly based on surgical removal. In fact, it was re-
ported that hypertrophic adenoids of allergic children under-
going sublingual immunotherapy (SLIT) have the typical re-
sponse to the specific allergen administered by the treatment, 
thus suggesting we reconsider their immunological role [32].
Conclusions
AIT was judged as appropriate in 28.6% of patients allergic to 
grass pollen and in 22.7% of patients allergic to dust mites, 
while the ranking was reversed (31.3% of mite-allergic patients 
and 28.6% of grass pollen-allergic patients), but not signifi-
cantly different, in the pediatric part of the SURF study [12]. 
The perception of a greater indication of AIT for the more se-
vere AR is in agreement with specific studies demonstrating 
the ability of AIT to work in drug-resistant AR. In particular, 
in a controlled trial on 410 AR patients unresponsive to drug 
treatment, a good response to subcutaneous immunothera-
py was reported [33], and such an outcome was recently con-
firmed in a real-life study using SLIT by 5-grass pollen tablets 
[34]. Therefore, targeting the patients with severe AR not con-
trolled by drugs needs the attention of the specialists involved 
in diagnosis and treatment of AR to provide to patients with 
an effective therapy.
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